OncologyImmuno-oncologyImmunology & inflammationRespiratory disease Exposure-response

Nivolumab exposure and tumor-size dynamics

Reference paper ↗

An exposure-response model connecting nivolumab steady-state exposure to competing tumor shrinkage and progression processes and their resulting tumor-size trajectory.

Therapeutic
Nivolumab
Modality
Monoclonal antibody
Target
PD-1 / PDCD1
Disease
Melanoma, non-small cell lung cancer, and renal cell carcinoma
Model type
Exposure-response

Complete model workspace

Checking workspace access…

Parameters
12
States
4
Equations
4
Derived outputs
6

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

joint MEL 3 mg/kg, Cminss 85 ug/mL

How does nivolumab exposure shift the balance between tumor shrinkage and progression? Explore this biological starting configuration through Steady-state trough concentration, Tumor size, Tumor size relative to baseline.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–52 week; step 0.25

InputDefaultAvailable range
Steady-state trough concentration85 ug/mL42.5–127.5 ug/mL
Maximum tumor shrinkage rate0.01455 1/week0.007277–0.02183 1/week
Tumor-shrinkage half-maximal concentration56.89 ug/mL28.45–85.34 ug/mL
Minimum tumor progression rate0.1776 mm/week0.08881–0.2664 mm/week
Tumor-progression half-maximal concentration10.33 ug/mL5.164–15.49 ug/mL

Expected readouts

Steady-state trough concentration · Tumor size (mm) · Tumor size relative to baseline (percent)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 12 declared model parameters.

More key parameters (1)

How the model represents the biology

An exposure-response model connecting nivolumab steady-state exposure to competing tumor shrinkage and progression processes and their resulting tumor-size trajectory.

How does fixed nivolumab trough exposure shift tumor shrinkage and progression?A scenario-defined steady-state nivolumab trough concentration independently changes an empirical tumor-shrinkage rate and tumor-progression rate. Those opposing drives determine the exploratory tumor-size trajectory.BIOLOGY OVERVIEWHow does fixed nivolumab trough exposure shift tumor shrinkage and progression?Fixed trough exposureScenario-defined nivolumabCminssShrinkage driveExposure-dependent empiricalrateProgression driveExposure-dependent empiricalrateTumor sizeNet shrinkage and progressionPRIMARY READOUTSSteady-state trough exposureSteady-state trough exposu…Exploratory tumor sizeExploratory tumor sizeTumor size relative to baselineTumor size relative to bas…

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Nivolumab dosing or PK, clearance, PD-1 binding or occupancy, immune-cell activation, population variability, and causal dose recommendations are not represented.

Modeled relationships (4)
  • Fixed trough exposure → Shrinkage drive: sets shrinkage (modulation)
  • Fixed trough exposure → Progression drive: sets progression (modulation)
  • Shrinkage drive → Tumor size: tumor reduction (loss)
  • Progression drive → Tumor size: tumor increase (production)

Modeled relationships: Fixed trough exposure to Shrinkage drive: sets shrinkage (modulation); Fixed trough exposure to Progression drive: sets progression (modulation); Shrinkage drive to Tumor size: tumor reduction (loss); Progression drive to Tumor size: tumor increase (production).

Primary readouts: Steady-state trough exposure; Exploratory tumor size; Tumor size relative to baseline.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID agrawal_2016_nivolumab_dose_selection_er_tgd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics